Highmark has made a $25 million grant to Penn State Health to expand cancer research, improve access to drug trials for patients and to develop new medicines, the Pittsburgh-based insurer announced on Thursday.
The funding is the first financial commitment to Penn State Health since Highmark partnered with the Hershey, Pa.-based health system in December. Highmark, a health insurance company that also operates a hospital network, and Penn State Health are involved in a long-term partnership that includes a joint investment of $1 billion to develop a community-based health care services.
“This is all part of our population health strategy,” Highmark President and CEO David Holmberg said. “We’d rather keep people close to home, in an environment where they have the best shot at the best outcomes.”
Cancer is the second leading cause of death for Pennsylvanians, state Secretary of Health Rachel Levine said at the Highmark announcement.
Ray Hohl, director of the Penn State Cancer Institute, said the grant comes at an “absolutely critical time,” partly because it will accelerate promising research that’s already underway.
“It’s really transformative,” he said.
Penn State Health is a multi-hospital health system that serves patients in 29 counties of central Pennsylvania. Thursday’s announcement was made at the Milton S. Hershey Medical Center in Hershey, where the Penn State Cancer Institute is also located.
Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.